Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


At-home genetic tests scrutinized

This article was originally published in The Gray Sheet

Executive Summary

"No at-home genetic tests have been reviewed by the FDA, and the FDA has not evaluated the accuracy of their claims," writes the Federal Trade Commission in a July 27 consumer fact sheet. FTC notes that at-home genetic tests, which range in price from $295 to $1,200, are not backed by "valid scientific studies" showing their safety and efficacy. "Because of the complexities involved in both the testing and the interpretation of the results, genetic tests should be performed in a specialized laboratory," with results interpreted by a clinician, the fact sheet notes. FTC has been criticized for its limited oversight of genetic testing claims (1"The Gray Sheet" Nov. 3, 2003, p. 16)...

You may also be interested in...

Serious Disease Genetic Testing Claims More Likely To Prompt FTC Action

The Federal Trade Commission's limited oversight of regional laboratories and genetic test promotional claims for non-life-threatening diseases is eliciting concern from the HHS Secretary's Advisory Committee on Genetics, Health & Society

Oxford/AZ’s COVID-19 Vaccine Cuts Virus Spread By 60%

Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.

GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches

After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts